Studies how doctors choose first treatment for advanced bladder cancer
Observes why doctors pick platinum chemotherapy for adults with metastatic urothelial carcinoma.
Plain-language title generated from the registry record
Registry title: Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma
Key facts
- Where
- Strasbourg, FranceSee the site
Where in France
- Service Oncologie Médicale - CHU de Strasbourg - FranceStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07339878
- Record updated
- 14 January 2026
- Original description
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.Read full original descriptionShow less
Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma: Observational, Multicenter, Real-world Study
The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Inclusion: Patients over 18 years of age; Metastatic urothelial carcinoma; Treated with first-line metastatic therapy since October 2024.
Exclusion: Patient who expressed opposition to participating in the study.